Amino Acid Solutions for <sup>177</sup>Lu-Oxodotreotide Premedication: A Tolerance Study
Background: The co-infusion of amino acid solutions during peptide receptor radionuclide therapy reduces the tubular reabsorption of <sup>177</sup>Lu-oxodotreotide, thus minimizing nephrotoxicity. In our nuclear medicine department, the patients received two different types of amino acid...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/21/5212 |
| _version_ | 1797468893777756160 |
|---|---|
| author | Pierre Courault Agathe Deville Vincent Habouzit Frédéric Gervais Claire Bolot Claire Bournaud Elise Levigoureux |
| author_facet | Pierre Courault Agathe Deville Vincent Habouzit Frédéric Gervais Claire Bolot Claire Bournaud Elise Levigoureux |
| author_sort | Pierre Courault |
| collection | DOAJ |
| description | Background: The co-infusion of amino acid solutions during peptide receptor radionuclide therapy reduces the tubular reabsorption of <sup>177</sup>Lu-oxodotreotide, thus minimizing nephrotoxicity. In our nuclear medicine department, the patients received two different types of amino acid perfusion over time: a commercial solution (CS) containing 10% amino acids, and a 2.5% lysine–arginine (LysArg) hospital preparation, produced by a referral laboratory. The aim of the present study was to analyze the tolerance of the two amino acid solutions. Methods: The patient files were analyzed and double-checked. The study parameters comprised the gender, age, primary tumor site, type of amino acid perfusion, adverse events (AE) and WHO AE grades, antiemetic premedication, creatinine, and serum potassium level. Results: From February 2016 to February 2019, 76 patients were treated, for a total 235 cycles. AEs occurred in 71% of the CS cycles (<i>n</i> = 82/116), versus 18% (<i>n</i> = 21/119) in the LysArg group (<i>p</i> < 0.0001). In the CS group, the AEs were mostly WHO grade 4 (<i>n</i> = 24/82), and mostly grade 1 in the LysArg group (<i>n</i> = 13/21). Poisson regression showed a higher risk of AE overall and of grades 3 and 4 in the females and with CS. The mean creatinine clearance was identical before and after the PRRT cycles, whichever amino acid perfusion was used. Conclusions: The lysine–arginine preparation showed better tolerance than the commercial solution. The change to LysArg reduced the antiemetic premedication from four molecules to one. |
| first_indexed | 2024-03-09T19:13:46Z |
| format | Article |
| id | doaj.art-f40c4cd411ce4aaa937f9aafb9a5b0ee |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T19:13:46Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f40c4cd411ce4aaa937f9aafb9a5b0ee2023-11-24T04:00:51ZengMDPI AGCancers2072-66942022-10-011421521210.3390/cancers14215212Amino Acid Solutions for <sup>177</sup>Lu-Oxodotreotide Premedication: A Tolerance StudyPierre Courault0Agathe Deville1Vincent Habouzit2Frédéric Gervais3Claire Bolot4Claire Bournaud5Elise Levigoureux6Hospices Civils de Lyon, Groupement Hospitalier Est, 69677 Bron, FranceHospices Civils de Lyon, Groupement Hospitalier Est, 69677 Bron, FranceHospices Civils de Lyon, Groupement Hospitalier Est, 69677 Bron, FranceService de Pharmacie, Groupement Hospitalier Centre, Hospices Civils de Lyon, 69003 Lyon, FranceHospices Civils de Lyon, Groupement Hospitalier Est, 69677 Bron, FranceHospices Civils de Lyon, Groupement Hospitalier Est, 69677 Bron, FranceHospices Civils de Lyon, Groupement Hospitalier Est, 69677 Bron, FranceBackground: The co-infusion of amino acid solutions during peptide receptor radionuclide therapy reduces the tubular reabsorption of <sup>177</sup>Lu-oxodotreotide, thus minimizing nephrotoxicity. In our nuclear medicine department, the patients received two different types of amino acid perfusion over time: a commercial solution (CS) containing 10% amino acids, and a 2.5% lysine–arginine (LysArg) hospital preparation, produced by a referral laboratory. The aim of the present study was to analyze the tolerance of the two amino acid solutions. Methods: The patient files were analyzed and double-checked. The study parameters comprised the gender, age, primary tumor site, type of amino acid perfusion, adverse events (AE) and WHO AE grades, antiemetic premedication, creatinine, and serum potassium level. Results: From February 2016 to February 2019, 76 patients were treated, for a total 235 cycles. AEs occurred in 71% of the CS cycles (<i>n</i> = 82/116), versus 18% (<i>n</i> = 21/119) in the LysArg group (<i>p</i> < 0.0001). In the CS group, the AEs were mostly WHO grade 4 (<i>n</i> = 24/82), and mostly grade 1 in the LysArg group (<i>n</i> = 13/21). Poisson regression showed a higher risk of AE overall and of grades 3 and 4 in the females and with CS. The mean creatinine clearance was identical before and after the PRRT cycles, whichever amino acid perfusion was used. Conclusions: The lysine–arginine preparation showed better tolerance than the commercial solution. The change to LysArg reduced the antiemetic premedication from four molecules to one.https://www.mdpi.com/2072-6694/14/21/5212<sup>177</sup>Lu-oxodotreotidepeptide receptor radionuclide therapypremedicationamino acid perfusion |
| spellingShingle | Pierre Courault Agathe Deville Vincent Habouzit Frédéric Gervais Claire Bolot Claire Bournaud Elise Levigoureux Amino Acid Solutions for <sup>177</sup>Lu-Oxodotreotide Premedication: A Tolerance Study Cancers <sup>177</sup>Lu-oxodotreotide peptide receptor radionuclide therapy premedication amino acid perfusion |
| title | Amino Acid Solutions for <sup>177</sup>Lu-Oxodotreotide Premedication: A Tolerance Study |
| title_full | Amino Acid Solutions for <sup>177</sup>Lu-Oxodotreotide Premedication: A Tolerance Study |
| title_fullStr | Amino Acid Solutions for <sup>177</sup>Lu-Oxodotreotide Premedication: A Tolerance Study |
| title_full_unstemmed | Amino Acid Solutions for <sup>177</sup>Lu-Oxodotreotide Premedication: A Tolerance Study |
| title_short | Amino Acid Solutions for <sup>177</sup>Lu-Oxodotreotide Premedication: A Tolerance Study |
| title_sort | amino acid solutions for sup 177 sup lu oxodotreotide premedication a tolerance study |
| topic | <sup>177</sup>Lu-oxodotreotide peptide receptor radionuclide therapy premedication amino acid perfusion |
| url | https://www.mdpi.com/2072-6694/14/21/5212 |
| work_keys_str_mv | AT pierrecourault aminoacidsolutionsforsup177supluoxodotreotidepremedicationatolerancestudy AT agathedeville aminoacidsolutionsforsup177supluoxodotreotidepremedicationatolerancestudy AT vincenthabouzit aminoacidsolutionsforsup177supluoxodotreotidepremedicationatolerancestudy AT fredericgervais aminoacidsolutionsforsup177supluoxodotreotidepremedicationatolerancestudy AT clairebolot aminoacidsolutionsforsup177supluoxodotreotidepremedicationatolerancestudy AT clairebournaud aminoacidsolutionsforsup177supluoxodotreotidepremedicationatolerancestudy AT eliselevigoureux aminoacidsolutionsforsup177supluoxodotreotidepremedicationatolerancestudy |